PERSONALIS INC (PSNL) Stock Overview
USA - NASDAQ:PSNL - US71535D1063 - Common Stock
PSNL Key Statistics, Chart & Performance
The current stock price of PSNL is 9.55 USD. In the past month the price increased by 49.54%. In the past year, price increased by 91.55%.
PSNL Latest News, Press Relases and Analysis
PSNL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 24.92 | 210.82B | ||
| DHR | DANAHER CORP | 27.76 | 153.24B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 143.51 | 46.81B | ||
| A | AGILENT TECHNOLOGIES INC | 26.28 | 40.60B | ||
| IQV | IQVIA HOLDINGS INC | 18.73 | 37.03B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 34.09 | 28.72B | ||
| WAT | WATERS CORP | 28.08 | 20.44B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 40.29 | 20.48B | ||
| MEDP | MEDPACE HOLDINGS INC | 40.88 | 16.42B | ||
| TEM | TEMPUS AI INC | N/A | 15.43B | ||
| ILMN | ILLUMINA INC | 22.84 | 14.61B | ||
| ICLR | ICON PLC | 12.58 | 12.91B |
Related stock screener links
About PSNL
Company Profile
Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The company is headquartered in Fremont, California and currently employs 229 full-time employees. The company went IPO on 2019-06-20. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. The firm performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and the development of personalized cancer therapies.
Company Info
PERSONALIS INC
6600 Dumbarton Circle
Fremont CALIFORNIA 94025 US
CEO: John West
Employees: 229
Phone: 16507521300
PERSONALIS INC / PSNL FAQ
Can you describe the business of PERSONALIS INC?
Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The company is headquartered in Fremont, California and currently employs 229 full-time employees. The company went IPO on 2019-06-20. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. The firm performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and the development of personalized cancer therapies.
What is the current price of PSNL stock?
The current stock price of PSNL is 9.55 USD. The price decreased by -2.05% in the last trading session.
Does PSNL stock pay dividends?
PSNL does not pay a dividend.
What is the ChartMill technical and fundamental rating of PSNL stock?
PSNL has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What do analysts say about PERSONALIS INC (PSNL) stock?
14 analysts have analysed PSNL and the average price target is 7.2 USD. This implies a price decrease of -24.57% is expected in the next year compared to the current price of 9.55.
How is the valuation of PERSONALIS INC (PSNL) based on its PE ratio?
PERSONALIS INC (PSNL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.28).
What is PERSONALIS INC worth?
PERSONALIS INC (PSNL) has a market capitalization of 846.89M USD. This makes PSNL a Small Cap stock.
PSNL Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to PSNL. When comparing the yearly performance of all stocks, PSNL is one of the better performing stocks in the market, outperforming 95.14% of all stocks.
PSNL Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to PSNL. The financial health of PSNL is average, but there are quite some concerns on its profitability.
PSNL Financial Highlights
Over the last trailing twelve months PSNL reported a non-GAAP Earnings per Share(EPS) of -1.28. The EPS increased by 15.79% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -35.3% | ||
| ROE | -47.85% | ||
| Debt/Equity | 0 |
PSNL Forecast & Estimates
14 analysts have analysed PSNL and the average price target is 7.2 USD. This implies a price decrease of -24.57% is expected in the next year compared to the current price of 9.55.
For the next year, analysts expect an EPS growth of 28.2% and a revenue growth -12.47% for PSNL